A Phase 3 interventional study of nivolumab and Placebo in Urinary Bladder Neoplasms, sponsored by Bristol-Myers Squibb. Terminated at 63 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing nivolumab in Urinary Bladder Neoplasms — 3 open to participants now, 11 under way, none of them phase 3. Nivolumab · Urinary Bladder Neoplasms.
Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, this one is the 24th largest by enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 17th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →3 of the 25 studies testing nivolumab in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 15 · Phase 3 4
First in 2015; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 76 across the 25 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
11 studies in Urinary Bladder Neoplasms by Bristol-Myers Squibb: 1 open now, 1 under way, 1 of them phase 3. Of 10 finished, 3 (30%) have results posted.
Among the 11 studies in Urinary Bladder Neoplasms by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2020, is one of 3 in phase 3, and was the 7th registered.
Bristol-Myers Squibb’s Urinary Bladder Neoplasms studies by the year they started, since 2005.
4 of the studies testing nivolumab in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06237920The Netherlands Cancer InstituteStage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | 2026-12-01 |
| NCT03520491Memorial Sloan Kettering Cancer CenterA Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | 2027-01 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
| NCT02496208National Cancer Institute (NCI)Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 11 in Urinary Bladder Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study comparing nivolumab and bacterial drugs given to help the body's immune system in the bladder versus bacterial drugs alone in high risk bladder cancer participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: nivolumab · Biological: Bacillus Calmette-Guérin (BCG)
Other: Placebo · Biological: Bacillus Calmette-Guérin (BCG)
Specified Dose on Specified Days
Specified Dose on Specified Days
Specified Dose on Specified Days
Part 2: Event Free Survival
The time between the date of randomization and the date of first documented event or death due to any cause, whichever occurs first. Events include recurrence of disease (TaHG, T1, or CIS) and progression of disease. Data Not Collected (DNC)
Time frame: Approximately 44 Months and 1 Week
Part 2: Worsening-Free Survival
The time from randomization to progression to muscle-invasive disease (ie, T2), cystectomy, systemic chemotherapy, radiotherapy, or death from any cause. Data Not Collected (DNC)
Time frame: Approximately 44 months and 1 week
Part 2: Overall Survival
The time between the date of randomization and the date of death due to any cause. For participants still alive, OS is censored at the last date the participant is known to be alive. Data Not Collected (DNC)
Time frame: Approximately 44 months and 1 week
Part 2: Complete Response Rate at 13 Weeks
CRR is defined as the proportion of participants with CIS (+/- TaHG/T1) per PRC at randomization who are disease free at the first disease assessment (Week 13) Data Not Collected (DNC)
Time frame: 13 Weeks
Part 2: Duration of Response
the time between the date of the first CR to the date of first documented recurrence, progression, or death due to any cause. Data Not Collected (DNC)
Time frame: Approximately 44 months and 1 week
All-causality Adverse Events Leading to Discontinuation
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.
Time frame: 24.6 months
All-causality Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.
Time frame: 24.6 months
Drug-related Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.
Time frame: 24.6 months
| Milestone | Arm A | Arm B |
|---|---|---|
| Started | 8 | 4 |
| Completed | 8 | 4 |
| Not completed | 0 | 0 |
The time between the date of randomization and the date of first documented event or death due to any cause, whichever occurs first. Events include recurrence of disease (TaHG, T1, or CIS) and progression of disease. Data Not Collected (DNC)
No measurements were reported for this outcome.
The time from randomization to progression to muscle-invasive disease (ie, T2), cystectomy, systemic chemotherapy, radiotherapy, or death from any cause. Data Not Collected (DNC)
No measurements were reported for this outcome.
The time between the date of randomization and the date of death due to any cause. For participants still alive, OS is censored at the last date the participant is known to be alive. Data Not Collected (DNC)
No measurements were reported for this outcome.
CRR is defined as the proportion of participants with CIS (+/- TaHG/T1) per PRC at randomization who are disease free at the first disease assessment (Week 13) Data Not Collected (DNC)
No measurements were reported for this outcome.
the time between the date of the first CR to the date of first documented recurrence, progression, or death due to any cause. Data Not Collected (DNC)
No measurements were reported for this outcome.
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.
| Participants | Arm A | Arm B |
|---|---|---|
| Any Grade | 1 | 3 |
| Grade 3-4 | 0 | 0 |
| Grade 5 | 0 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.
| Participants | Arm A | Arm B |
|---|---|---|
| Grade 1 | 1 | 2 |
| Grade 2 | 4 | 1 |
| Grade 3 | 1 | 1 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be based on NCI CTCAE version 5.0 criteria.
| Participants | Arm A | Arm B |
|---|---|---|
| Grade 1 | 1 | 1 |
| Grade 2 | 4 | 1 |
| Grade 3 | 1 | 1 |
Collected over Adverse Events and Serious Adverse Events: (From first dose to last dose + 100 days): Approximately 44 months and 1 week All-Cause mortality (From randomization to end of study): Approximately 44 months and 1 week. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A | 0/8 (0%) | 2/8 (25%) | 5/8 (62.5%) |
| Arm B | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | Arm A | Arm B |
|---|---|---|
| CystitisInfections and infestations | 1/8 | 0/4 |
| Urinary tract infectionInfections and infestations | 1/8 | 0/4 |
| Event | Arm A | Arm B |
|---|---|---|
| Urinary tract infectionInfections and infestations | 3/8 | 3/4 |
| DysuriaRenal and urinary disorders | 3/8 | 1/4 |
| AnaemiaBlood and lymphatic system disorders | 2/8 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 2/8 | 0/4 |
| Umbilical herniaGastrointestinal disorders | 0/8 | 1/4 |
| AstheniaGeneral disorders | 0/8 | 1/4 |
| PainGeneral disorders | 0/8 | 1/4 |
| CystitisInfections and infestations | 1/8 | 1/4 |
| GastroenteritisInfections and infestations | 0/8 | 1/4 |
| Cortisol decreasedInvestigations | 0/8 | 1/4 |
| Age, Continuous(Years) | Arm A | Arm B | Total |
|---|---|---|---|
| Mean | 61.1 ± 9.8 | 73.0 ± 15.3 | 65.1 ± 12.6 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 7 | 3 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 5 | 1 | 6 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 7 | 4 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2020 to primary completion in Oct 2023, 45 months.
Results were first posted in Sep 2025, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab